2.965
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - USA Today
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - TipRanks
Market Fear: Can Lixte Biotechnology Holdings Inc. Equity Warrant be recession proofFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Lixte Biotechnology Raises CEO Compensation Amid Leadership Support - TipRanks
Lixte (NASDAQ: LIXT) lifts CEO Geordan Pursglove base salary to $360k - Stock Titan
Lixte Biotechnology boosts CEO Geordan Pursglove's base salary to $360,000 - TradingView
Lixte Biotechnology stock faces scrutiny amid stalled pipeline progress and biotech sector volatilit - AD HOC NEWS
Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN
Guidance Update: Is Lixte Biotechnology Holdings Inc a stock for growth or value investorsWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Breakout Move: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proofWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Faces Short-Term Pressure Amid Strong Rising Trend an - AD HOC NEWS
Bond Watch: Does Lixte Biotechnology Holdings Inc align with a passive investing strategyOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
LIXTE Biotechnology and Liora Technologies Partner to Advance Combined Cancer Treatment Approach - citybuzz -
Aug PostEarnings: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proof2026 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Trades Steadily Amid Clinical-Stage Oncology Focus - AD HOC NEWS
Is Lixte Biotechnology Holdings Inc stock technically oversold2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
LIXTE Biotechnology Expands Ovarian Cancer Trial Through MD Anderson and GSK Partnership - citybuzz -
Lixte Amends Share Exchange, Clarifies Liora Ownership Structure - The Globe and Mail
Lixte Biotechnology Enters Amended Share Exchange to Consolidate Liora Ownership With Orbit Capital - TradingView
Lixte (NASDAQ: LIXT) restates Liora share exchange and Orbit’s 20% stake - Stock Titan
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline - TipRanks
LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research - TradingView
Powell Max Limited Successfully Repositions for Its Next Phase of Growth - The Manila Times
Aug Sectors: Whats the profit margin of Lixte Biotechnology Holdings IncWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Trade Report: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Volatility Watch: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantWeekly Stock Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Why Lixte Biotechnology Holdings Inc. stock attracts high net worth investorsMarket Risk Analysis & Safe Entry Point Alerts - Naître et grandir
Wall Street Recap: Why is Lixte Biotechnology Holdings Inc Equity Warrant stock going downDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
MACD Signal: How does Lixte Biotechnology Holdings Inc Equity Warrant perform in inflationary periodsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
LIXTW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - Digital Journal
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - Digital Journal
Downgrade Watch: Will Lixte Biotechnology Holdings Inc stock go up in YEARJuly 2025 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Should I Buy LIXT? LIXT 2026 AnalysisIntellectia AI™ - Intellectia AI
LIXTWLixte Biotechnology Hldgs Inc Latest Stock News & Market Updates - Stock Titan
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - USA Today
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - USA Today
Should I invest in Lixte Biotechnology Holdings Inc. before earningsJuly 2025 Chart Watch & Expert Approved Trade Ideas - mfd.ru
Is Lixte Biotechnology Holdings Inc. stock a value trap2025 Stock Rankings & Accurate Entry and Exit Point Alerts - mfd.ru
Why Lixte Biotechnology Holdings Inc. stock could rally in 2025July 2025 WrapUp & Precise Swing Trade Alerts - mfd.ru
What is the next catalyst for Lixte Biotechnology Holdings Inc. Equity WarrantWeekly Loss Report & Verified Trade Idea Suggestions - mfd.ru
Will Lixte Biotechnology Holdings Inc. stock go up in YEARJuly 2025 Summary & Community Verified Trade Signals - mfd.ru
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary By Investing.com - Investing.com India
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - NewMediaWire
Lixte Elevates Liora Leadership to Advance Proton Therapy - TipRanks
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary - Investing.com
Lixte Biotechnology appoints Sidney Braun as CEO, Liora - TipRanks
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):